Executive Manmeet Singh Soni buys 50K Summit Therapeutics (SMMT) shares

Rhea-AI Filing Summary

Summit Therapeutics Inc. director and executive officer Manmeet Singh Soni, who serves as COO and CFO, reported open-market purchases of the company’s common stock. On June 4, 2026, he bought 25,000 shares at $14.43 and another 25,000 shares at $14.46.

These transactions total 50,000 shares of Summit Therapeutics common stock acquired in the open market, leaving him with a direct ownership stake of more than three million shares.

Insider Trade Summary

Net Buyer: 50,000 shares ($722,250)

Net Buy 2 txns

Insider Soni Manmeet Singh

Role COO and CFO

Bought 50,000 shs ($722K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	25,000	$14.46	$362K
Purchase	Common Stock	25,000	$14.43	$361K

Holdings After Transaction: Common Stock — 3,098,603 shares (Direct, null)

Footnotes (1)

Key Figures

Open-market purchase 1: 25,000 shares at $14.43 Open-market purchase 2: 25,000 shares at $14.46 Total shares bought: 50,000 shares +1 more

4 metrics

Open-market purchase 1 25,000 shares at $14.43 Common Stock, June 4, 2026

Open-market purchase 2 25,000 shares at $14.46 Common Stock, June 4, 2026

Total shares bought 50,000 shares Net buy across two transactions

Net buy/sell direction net-buy, 50,000 shares Transaction summary for this Form 4

Key Terms

Form 4, open-market purchase, non-derivative, Common Stock, +1 more

5 terms

Form 4 regulatory

"This Summit Therapeutics insider activity is disclosed on a Form 4 filing."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

open-market purchase financial

"Each transaction is coded as an open-market purchase of Common Stock."

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

non-derivative financial

"Both entries are classified as non-derivative transactions in Common Stock."

Common Stock financial

"The security title for each transaction is listed as Common Stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

direct ownership financial

"Ownership type for these trades is reported as direct ownership by the insider."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Soni Manmeet Singh

(Last) (First) (Middle)

C/O SUMMIT THERAPEUTICS INC.

601 BRICKELL KEY DRIVE, SUITE 1000

(Street)

MIAMI FLORIDA 33131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Summit Therapeutics Inc. [ SMMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COO and CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		P		25,000	A	$14.46	3,098,603	D
Common Stock	06/04/2026		P		25,000	A	$14.43	3,123,603	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Manmeet Soni	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Summit Therapeutics (SMMT) report on this Form 4?

Summit Therapeutics reported that executive Manmeet Singh Soni purchased 50,000 shares of common stock in open-market transactions. The trades occurred on June 4, 2026, across two separate 25,000-share buys at prices of $14.43 and $14.46 per share.

Who is the insider buying Summit Therapeutics (SMMT) shares on this Form 4?

The insider is Manmeet Singh Soni, a director and executive officer of Summit Therapeutics, serving as both COO and CFO. He reported direct, open-market purchases of the company’s common stock, increasing his already substantial personal holdings.

How many Summit Therapeutics (SMMT) shares did Manmeet Singh Soni buy?

Manmeet Singh Soni bought a total of 50,000 Summit Therapeutics common shares. The Form 4 shows two non-derivative transactions of 25,000 shares each, executed on June 4, 2026, as open-market purchases at prices slightly above $14 per share.

At what prices were the Summit Therapeutics (SMMT) insider purchases made?

The insider purchases were made at $14.43 and $14.46 per share. Each price corresponds to a 25,000-share open-market transaction in Summit Therapeutics common stock on June 4, 2026, as disclosed in the Form 4 filing.

Are the Summit Therapeutics (SMMT) insider trades direct or through an entity?

The trades are reported as directly owned by Manmeet Singh Soni. The Form 4 classifies both transactions as non-derivative, with ownership type marked as direct and no footnotes indicating that another entity holds voting or investment authority.

Does this Summit Therapeutics (SMMT) Form 4 show any insider share sales?

No, the Form 4 discloses only open-market purchases by Manmeet Singh Soni. The transaction summary shows two buy transactions totaling 50,000 shares and indicates no sales, gifts, tax withholdings, or derivative exercises in this filing.